A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

Abstract Background The patient population with stage III non-small-cell lung cancer (NSCLC) is heterogeneous, with varying staging characteristics and diverse treatment options. Despite the potential practice-changing implications of randomized controlled trials evaluating the efficacy of periopera...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Chieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, Chia-Hung Chen, Chih-Yen Tu, Te-Chun Hsia, Wen-Chien Cheng, Hung-Jen Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-09-01
Edice:	BMC Cancer
Témata:	Adenocarcinoma Chemotherapy Epidermal growth factor receptor (EGFR) Stage III Surgery Tyrosine kinase inhibitor (TKI)
On-line přístup:	https://doi.org/10.1186/s12885-023-11342-y
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!